Mark Bloch

Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study

Andrew E. Grulich, Rebecca Guy, Janaki Amin et al. · The Lancet HIV · 2018 · 369 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +17

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

Naomi Schlesinger, Rieke Alten, Thomas Bardin et al. · Annals of the Rheumatic Diseases · 2012 · 346 citations

Medicine, Pharmacotherapy, Inflammation +16

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

Jürgen K. Rockstroh, Mark Nelson, Christine Katlama et al. · The Lancet HIV · 2015 · 306 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1

Frank van Leth, Prahpan Phanuphak, Erik S.G. Stroes et al. · PLoS Medicine · 2004 · 276 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial

Allison Martin, Mark Bloch, Janaki Amin et al. · Clinical Infectious Diseases · 2009 · 222 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17